MarketPeel
Insider Trading Intelligence
Pricing
…
GP

Gary W. Pace

CRDF
DIRECTOR · CARDIFF ONCOLOGY, INC. · CIK 0001184778
FILING MIX · LIFETIME72%/28%
BUYS
44
SELLS
17
TOTAL VALUE
$10.72M
COMPANIES
2
ACTIVE SINCE
Mar 2020
HOLDINGS NOW
1,378,503
AVG SELL PX
$38.05
TRADE KIND
SHOWING 61 / 61
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
23 backtested trades · 8 horizons · 6 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Gary W. Pace, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d23+60.87%+12.63%-0.55%+13.17%+1.88%—
14d23+56.52%+15.78%+0.97%+14.81%-1.16%—
30d23+43.48%+14.32%+3.03%+11.28%-8.49%—
60d23+52.17%+25.43%+4.41%+21.02%-14.16%—
90d23+43.48%+45.85%+5.71%+40.14%-12.10%—
180d23+69.57%+57.26%+9.45%+47.81%-13.90%—
1y23(2 pending)+57.14%+12.39%+16.90%-4.51%-39.59%—
2y23(4 pending)+47.37%-36.90%+23.11%-60.00%-78.10%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
CRDF · 1,356,376 shares · as of Jun 18, 2026
0339,094678,1881,017,2821,356,376202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 44 buys / 17 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASE
30,000$1.22$36.6K1,356,376Jun 18, 2026Jun 22, 2026 ↗View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
40,565——228,104Jun 11, 2026Jun 15, 2026 ↗View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASE
275,000$2.45$673.8K1,330,676Jul 30, 2025Jul 31, 2025 ↗View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASE
15,000$2.45$36.8K1,345,676Jul 30, 2025Jul 31, 2025 ↗View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
40,565——187,539Jun 26, 2025Jun 27, 2025 ↗View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASE
11,500$2.60$29.9K1,059,376Dec 11, 2024Dec 12, 2024 ↗View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASE
350,115$2.60$910.3K1,047,876Dec 11, 2024Dec 12, 2024 ↗View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
29,700——146,974Jun 27, 2024Jul 1, 2024 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
SALE
90,000$30.60$2.75M22,127Mar 8, 2024Mar 8, 2024 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
SALE
28,257$30.81$870.6K112,127Mar 7, 2024Mar 8, 2024 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
SALE
1,066$29.67$31.6K140,384Mar 6, 2024Mar 8, 2024 ↗View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASE
30,000$1.37$41.1K697,761Dec 19, 2023Dec 19, 2023 ↗View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASE
22,950$0.98$22.5K667,761Nov 10, 2023Nov 14, 2023 ↗View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
27,700——117,274Jun 15, 2023Jun 20, 2023 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
1,775——141,450Jun 14, 2023Jun 16, 2023 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
12,925——12,925Jun 14, 2023Jun 16, 2023 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
PURCHASE
7,000$29.90$209.3K144,690May 11, 2023May 15, 2023 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
SALE
7,000——0May 11, 2023May 15, 2023 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
SALE
5,015$41.78$209.5K139,675May 11, 2023May 15, 2023 ↗View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASE
150,000$1.71$256.5K644,811Sep 15, 2022Sep 19, 2022 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
8,225——8,225Jun 8, 2022Jun 8, 2022 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
1,160——137,690Jun 8, 2022Jun 8, 2022 ↗View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
26,800——89,574Mar 9, 2022Mar 11, 2022 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
SALE
7,000——0Mar 3, 2022Mar 7, 2022 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
PURCHASE
7,000$10.81$75.7K136,530Mar 3, 2022Mar 7, 2022 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
PURCHASE
193$11.02$2.1K129,723Mar 1, 2022Mar 1, 2022 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
PURCHASE
1,166$11.02$12.8K130,889Mar 1, 2022Mar 1, 2022 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
SALE
1,359$67.75$92.1K129,530Mar 1, 2022Mar 1, 2022 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
SALE
193——0Mar 1, 2022Mar 1, 2022 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
SALE
1,166——0Mar 1, 2022Mar 1, 2022 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
PURCHASE
18,834$11.02$207.6K158,171Feb 28, 2022Mar 1, 2022 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
SALE
18,834——1,166Feb 28, 2022Mar 1, 2022 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
SALE
28,641$66.83$1.91M129,530Feb 28, 2022Mar 1, 2022 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
PURCHASE
9,807$11.02$108.1K139,337Feb 28, 2022Mar 1, 2022 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
SALE
9,807——193Feb 28, 2022Mar 1, 2022 ↗View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASE
30,000$6.75$202.5K494,811Sep 21, 2021Sep 22, 2021 ↗View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
22,000——62,774Jun 10, 2021Jun 14, 2021 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
7,626——7,626Jun 9, 2021Jun 11, 2021 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
1,066——129,530Jun 9, 2021Jun 11, 2021 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
SALEGRANT
Gift
1,485——128,464May 13, 2021Jun 11, 2021 ↗View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASE
5,000$10.20$51.0K459,811Mar 23, 2021Mar 24, 2021 ↗View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASE
2,500$10.21$25.5K462,311Mar 23, 2021Mar 24, 2021 ↗View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASE
2,500$10.31$25.8K464,811Mar 23, 2021Mar 24, 2021 ↗View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASE
2,000$10.54$21.1K454,811Mar 18, 2021Mar 19, 2021 ↗View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASE
1,000$10.58$10.6K452,811Mar 18, 2021Mar 19, 2021 ↗View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASE
1,500$9.27$13.9K451,811Mar 4, 2021Mar 4, 2021 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
PURCHASE
70,000$16.67$1.17M129,949Sep 25, 2020Sep 29, 2020 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
SALE
70,000——0Sep 25, 2020Sep 29, 2020 ↗View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASE
1,700$5.69$9.7K449,461Sep 16, 2020Sep 16, 2020 ↗View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASE
850$5.71$4.9K450,311Sep 16, 2020Sep 16, 2020 ↗View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
28,858——40,774Jun 17, 2020Jun 19, 2020 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
1,260——59,949Jun 9, 2020Jun 11, 2020 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
8,027——8,027Jun 9, 2020Jun 11, 2020 ↗View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASE
447,761$1.34$600.0K447,761May 11, 2020May 13, 2020 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
PURCHASE
4,649$1.61$7.5K46,251Mar 12, 2020Mar 16, 2020 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
PURCHASE
4,649$1.61$7.5K41,602Mar 12, 2020Mar 16, 2020 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
PURCHASE
5,000$13.98$69.9K58,689Mar 12, 2020Mar 16, 2020 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
SALE
7,438——0Mar 12, 2020Mar 16, 2020 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
SALE
5,000——0Mar 12, 2020Mar 16, 2020 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
SALE
4,649——0Mar 12, 2020Mar 16, 2020 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
PURCHASE
7,438$1.61$12.0K53,689Mar 12, 2020Mar 16, 2020 ↗View →
Other insiders · CRDF
Loading peer insiders…
About this filer
CIK 0001184778
ROLE
Director
PRIMARY
CRDF
COMPANIES
2
ACTIVE SINCE
Mar 2020
MARKETPEEL · /INSIDER/0001184778DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback